Business
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic ModalitiesReviewed Positive Data Across Late-Stage Neuropsychiatry Pipeline Including Osavampator and Direclidine; Topline Phase 3 Data from Both Programs Expected in 2027Announced Expansion of CRF Platform as Foundation of New Class of Medicines for Metabolic Diseases, Including ObesitySAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a new chapter in its research and development strategy, designed to fuel the Company's next era for growth and deliver long-term value. Neurocrine highlighted this business strategy during its 2025 R&D Day at its headquarters in San Diego, CA.\n \n \n \n \n \n \n \nBuilding on three decades of leadership in neurology, psychiatry, and endocrinology, Neurocrine is advancing a diversified pipeline of first- and best-in-class medicines across therapeutic modalities including two Phase 3 programs, osavampator for major depressive disorder and direclidine for schizophrenia. The company's clinical portfolio includes a rich pipeline of early- to mid-stage muscarinic agonists and VMAT2 inhibitors for the treatment of neuropsychiatric indications, and CRF-based therapies for metabolic diseases, including obesity. By the end of the decade, Neurocrine expects its R&D engine to deliver an approved medicine every two years.\"We are ushering in a new era for Neurocrine in which we accelerate the delivery of new medicines for patients,\" said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. \"Today, we unveiled the full breadth of our pipeline, featuring multiple first- and best-in-class assets targeting validated biological pathways and powered by an innovative R&D engine. With more than 30 years of leadership in CRF biology, we are now introducing a platform focused on CRF2, with the goal of developing novel therapies across a range of metabolic diseases. Our efforts will begin with obesity, where we believe we can deliver superior weight loss while preserving muscle mass.\"\"Backed by our proven track record in drug development and commercialization, the strong foundation we built with INGREZZA in neuropsychiatry and CRENESSITY in endocrinology, and an experienced team, we ar...